Cargando…

Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project

Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez, Enric, Betriu, Àngels, Yeramian, Andree, Fernández, Elvira, Purroy, Francesc, Sánchez-de-la-Torre, Manuel, Pamplona, Reinald, Miquel, Eva, Kerkeni, Mohsen, Hernández, Cristina, Simó, Rafael, Lecube, Albert, Hernández, Marta, Rius, Ferran, Polanco, Dinora, Barbé, Ferran, Torres, Gerard, Suárez, Guillermo, Portero-Otin, Manuel, Jové, Mariona, Colàs-Campàs, Laura, Benabdelhak, Ikram, Farràs, Cristina, Ortega, Marta, Valdivielso, José Manuel, Bermúdez-López, Marcelino, Martínez-Alonso, Montse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800392/
https://www.ncbi.nlm.nih.gov/pubmed/30842389
http://dx.doi.org/10.5551/jat.47498
_version_ 1783460432250404864
author Sánchez, Enric
Betriu, Àngels
Yeramian, Andree
Fernández, Elvira
Purroy, Francesc
Sánchez-de-la-Torre, Manuel
Pamplona, Reinald
Miquel, Eva
Kerkeni, Mohsen
Hernández, Cristina
Simó, Rafael
Lecube, Albert
Hernández, Marta
Rius, Ferran
Polanco, Dinora
Barbé, Ferran
Torres, Gerard
Suárez, Guillermo
Portero-Otin, Manuel
Jové, Mariona
Colàs-Campàs, Laura
Benabdelhak, Ikram
Farràs, Cristina
Ortega, Marta
Valdivielso, José Manuel
Bermúdez-López, Marcelino
Martínez-Alonso, Montse
author_facet Sánchez, Enric
Betriu, Àngels
Yeramian, Andree
Fernández, Elvira
Purroy, Francesc
Sánchez-de-la-Torre, Manuel
Pamplona, Reinald
Miquel, Eva
Kerkeni, Mohsen
Hernández, Cristina
Simó, Rafael
Lecube, Albert
Hernández, Marta
Rius, Ferran
Polanco, Dinora
Barbé, Ferran
Torres, Gerard
Suárez, Guillermo
Portero-Otin, Manuel
Jové, Mariona
Colàs-Campàs, Laura
Benabdelhak, Ikram
Farràs, Cristina
Ortega, Marta
Valdivielso, José Manuel
Bermúdez-López, Marcelino
Martínez-Alonso, Montse
author_sort Sánchez, Enric
collection PubMed
description Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study in which 2,568 non-diabetic subjects of both sexes without cardiovascular disease were included. Subcutaneous content of AGEs was assessed by skin autofluorescence (SAF) and subclinical atheromatous disease was measured by assessing the atheromatous plaque burden in carotid and femoral regions using ultrasonography. In addition, serum pentosidine, carboxymethyl-lysine (CML) and AGE receptors (RAGE) were assessed in a nested case-control study with 41 subjects without plaque and 41 individuals subjects with generalized disease. Results: Patients with atheromatous plaque had a higher SAF than those with no plaque (1.9 [1.7 to 2.3] vs. 1.8 [1.6 to 2.1] arbitrary units (AU), p % 0.001). The SAF correlated with the total number of affected regions (r = 0.171, p < 0.001), increasing progressively from 1.8 [1.6 to 2.1] AU in those without atheromatous disease to 2.3 [1.9 to 2.7] AU in patients with ≥ 8 plaques (p < 0.001). A correlation was also observed between SAF and the total plaque area (r = 0.113, p < 0.001). The area under the Receiver Operating Characteristic curve was 0.65 (0.61 to 0.68) for identifying male subjects with atheromatous disease. The multivariable logistic regression model showed a significant and independent association between SAF and the presence of atheromatous disease. However, no significant differences in serum pentosidine, CML, and RAGE were observed. Conclusions: Increased subcutaneous content of AGEs is associated with augmented atheromatous plaque burden. Our results suggest that SAF may provide clinically relevant information to the current strategies for the evaluation of cardiovascular risk, especially among the male population.
format Online
Article
Text
id pubmed-6800392
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-68003922019-10-25 Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project Sánchez, Enric Betriu, Àngels Yeramian, Andree Fernández, Elvira Purroy, Francesc Sánchez-de-la-Torre, Manuel Pamplona, Reinald Miquel, Eva Kerkeni, Mohsen Hernández, Cristina Simó, Rafael Lecube, Albert Hernández, Marta Rius, Ferran Polanco, Dinora Barbé, Ferran Torres, Gerard Suárez, Guillermo Portero-Otin, Manuel Jové, Mariona Colàs-Campàs, Laura Benabdelhak, Ikram Farràs, Cristina Ortega, Marta Valdivielso, José Manuel Bermúdez-López, Marcelino Martínez-Alonso, Montse J Atheroscler Thromb Original Article Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study in which 2,568 non-diabetic subjects of both sexes without cardiovascular disease were included. Subcutaneous content of AGEs was assessed by skin autofluorescence (SAF) and subclinical atheromatous disease was measured by assessing the atheromatous plaque burden in carotid and femoral regions using ultrasonography. In addition, serum pentosidine, carboxymethyl-lysine (CML) and AGE receptors (RAGE) were assessed in a nested case-control study with 41 subjects without plaque and 41 individuals subjects with generalized disease. Results: Patients with atheromatous plaque had a higher SAF than those with no plaque (1.9 [1.7 to 2.3] vs. 1.8 [1.6 to 2.1] arbitrary units (AU), p % 0.001). The SAF correlated with the total number of affected regions (r = 0.171, p < 0.001), increasing progressively from 1.8 [1.6 to 2.1] AU in those without atheromatous disease to 2.3 [1.9 to 2.7] AU in patients with ≥ 8 plaques (p < 0.001). A correlation was also observed between SAF and the total plaque area (r = 0.113, p < 0.001). The area under the Receiver Operating Characteristic curve was 0.65 (0.61 to 0.68) for identifying male subjects with atheromatous disease. The multivariable logistic regression model showed a significant and independent association between SAF and the presence of atheromatous disease. However, no significant differences in serum pentosidine, CML, and RAGE were observed. Conclusions: Increased subcutaneous content of AGEs is associated with augmented atheromatous plaque burden. Our results suggest that SAF may provide clinically relevant information to the current strategies for the evaluation of cardiovascular risk, especially among the male population. Japan Atherosclerosis Society 2019-10-01 /pmc/articles/PMC6800392/ /pubmed/30842389 http://dx.doi.org/10.5551/jat.47498 Text en 2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Sánchez, Enric
Betriu, Àngels
Yeramian, Andree
Fernández, Elvira
Purroy, Francesc
Sánchez-de-la-Torre, Manuel
Pamplona, Reinald
Miquel, Eva
Kerkeni, Mohsen
Hernández, Cristina
Simó, Rafael
Lecube, Albert
Hernández, Marta
Rius, Ferran
Polanco, Dinora
Barbé, Ferran
Torres, Gerard
Suárez, Guillermo
Portero-Otin, Manuel
Jové, Mariona
Colàs-Campàs, Laura
Benabdelhak, Ikram
Farràs, Cristina
Ortega, Marta
Valdivielso, José Manuel
Bermúdez-López, Marcelino
Martínez-Alonso, Montse
Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title_full Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title_fullStr Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title_full_unstemmed Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title_short Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
title_sort skin autofluorescence measurement in subclinical atheromatous disease: results from the ilervas project
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800392/
https://www.ncbi.nlm.nih.gov/pubmed/30842389
http://dx.doi.org/10.5551/jat.47498
work_keys_str_mv AT sanchezenric skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT betriuangels skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT yeramianandree skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT fernandezelvira skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT purroyfrancesc skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT sanchezdelatorremanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT pamplonareinald skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT miqueleva skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT kerkenimohsen skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT hernandezcristina skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT simorafael skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT lecubealbert skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT hernandezmarta skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT riusferran skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT polancodinora skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT barbeferran skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT torresgerard skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT suarezguillermo skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT porterootinmanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT jovemariona skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT colascampaslaura skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT benabdelhakikram skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT farrascristina skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT ortegamarta skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT valdivielsojosemanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT bermudezlopezmarcelino skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject
AT martinezalonsomontse skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject